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Background: One important public health issue associated with opioid use today is the risk of hepatitis C (HCV)
infection. Although methadone maintenance may help to decrease HCV-related risk practices, HCV risk behaviors
persist and are strongly associated with specific substance use patterns, mental status and social context. The ANRS-
Methaville study gave us the opportunity to better disentangle the different relationships between these various
factors and HCV risk practices.
Methods: The ANRS-Methaville multisite randomized trial was designed to assess the feasibility of initiating methadone
in primary care by comparing it with methadone initiation in specialized centers. This study recruited 195 participants
initiating methadone maintenance and followed up for 12 months. Longitudinal data from this trial was used to
acquire a greater understanding of HCV risk practices and their pattern of correlates in this population. We selected 176
patients who had data on HCV risk practices at M0 and M12, accounting for 312 visits. HCV risk practices were defined
as follows: sharing needles or syringes, sharing drug paraphernalia, getting a tattoo or having a piercing in a
non-professional context, sharing toiletry items. To identify factors associated with HCV risk practices, we performed a
mixed logistic regression analysis.
Results: HCV risk practices were reported by 19% and 15% of participants at baseline and M12, respectively. After
adjustment for age, cocaine use and alcohol dependence as well as suicidal risk, living in a couple with a non-drug user
and in a couple with a drug user were both independent predictors of HCV risk practices (OR[CI95%] = 4.16 [1.42-12.12];
OR[CI95%] = 9.85 [3.13-31.06], respectively).
Conclusions: Identifying individuals at risk of HCV transmission during methadone treatment such as stimulant users,
alcohol dependent individuals, and those at suicidal risk is necessary to optimize response to treatment. Innovative
prevention approaches tailored to couples are also urgently needed and could decrease HCV-risk in this population.
The trial is registered with the French Agency of Pharmaceutical Products (ANSM) under the number 2008-A0277-48,
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Methadone maintenance treatment (MMT) is recognized
as the gold standard for effective treatment for opioid de-
pendence [1] as it can lead to a major reduction in the use
of [2] or total abstinence from illicit opioids [3]. Further-
more, MMT has other positive outcomes such as social
rehabilitation, improvement in psychological and psychi-
atric status and reduction in risk behaviors associated with
HIV and HCV transmission. In people who use drugs
(PWUD) and especially in people who inject drugs
(PWID), HCV infection prevention and re-infection after
being cured of HCV remain major public health issues.
Among PWID, the prevalence of HCV infection may be
very high [4] and this is the result not only of the current
lack of availability of a combined package of prompt pre-
ventive interventions at a national level [5] but also of in-
dividual risk factors. Indeed, this explains why HCV
prevalence varies so greatly, and is independent of the
prevalence of drug use. It is important to distinguish the
different levels of risk according to the practices engaged
in by individuals. Besides the sharing of syringes/needles
which is known to be the main route of HCV transmis-
sion [6], the sharing of other injecting paraphernalia [7] is
also considered a high risk route of HCV transmission.
Other lower risk factors have also been identified, such as
the sharing of straws in drug sniffing [8], getting tattoos or
piercings in a non-professional context [9] and the sharing
of personal toiletry items in a household context [10]. One
study has shown that HCV-positive patients are unaware
of the risk of certain routes of transmission, such as the
sharing of personal items including toothbrushes, razors
and nail scissors [11].
Although research has highlighted a reduction in in-
jection practices thanks to MMT programs [12] in
PWID, it is also acknowledged that such preventative in-
terventions alone may not have a strong enough impact
on reducing HCV incidence in drug users [13]. Accord-
ingly, we used data from the ANRS Methaville trial to
better document HCV risk practices in methadone pa-
tients and to investigate the influence of specific individ-
ual risk factors in order to suggest improvements in
standard preventive interventions like MMT.
Methods
Study design
The ANRS-Methaville study is a multi-site, open-label,
randomized, controlled, non-inferiority, pragmatic trial
designed to assess the feasibility of initiating methadone
in primary care by comparing methadone initiation in
specialized centers with methadone initiation provided
by primary care physicians. Between January 2009 and
January 2010, 195 men and women were recruited in 10
sites randomly allocated to initiate methadone in special-
ized centers (standard care) or in primary care physicians’offices. Individuals who had a triple dependence on opi-
oids, alcohol and benzodiazepines were not included in
the study. The full protocol is described elsewhere [14].
The study protocol was approved by the Ethics Commit-
tee of Persons Protection in Paris, France. All individuals
provided written, informed consent before participating in
the study.
At initiation, 3, 6 and 12 months (M0, M3, M6 and
M12 respectively), a medical questionnaire was filled in
by the physician. A self-reported questionnaire was com-
pleted by the patient during each medical visit. After
each medical visit, a computer-assisted telephone inter-
view (CATI) was conducted by trained, non-judgmental
staff. The primary outcome was abstinence from street-
opioids at 12 months (M12) (with an underlying 15%
non-inferiority hypothesis for PC).
Data collection
At enrollment, we collected the following information: 1)
Socio-demographic characteristics: gender, age, educational
level, children, employment status, housing (owner or
renter, living in family home, in a hospital or clinic, in a so-
cial care institution/hostel, in a friend’s home, in a hotel
room, no home, other); 2) History of drug use: history of
drug overdose, of drug injection, age at first regular drug
use and at first injection. Unstable housing was defined as
not being a home owner or renter. Employment status,
housing and living in a couple were evaluated again at M12.
Alcohol consumption was assessed at M0 and M12
using the Alcohol Use Disorders Test (AUDIT) with a
cut-off point ≥ 13 being used to identify alcohol depend-
ence [15].
At each follow-up visit, drug use and drug injection in
the previous month were assessed using the Opiate
Treatment Index (OTI) [16]. Individuals who reported
using cocaine or having injected drugs at least once in
the previous month were defined as cocaine users or
current injectors, respectively. The patient’s social net-
work was assessed at enrollment and M12, by asking
participants two questions, as follows: how much of the
time they lived with someone who consumed heroin in
the previous 6 months (dichotomized as follows: from
“all of the time” to “less than half of the time” vs.
“never”) and how many of the people who they were in
regular contact with had used drugs in the previous
6 months (dichotomized as follows: from “all” to “less
than half” vs. “none”).
We combined the two variables “living in a couple” and
“living with someone who consumed heroin” and obtained
four categories variables: “living alone”; “living in a couple
with a non-drug user”; “living with a drug user not in a
couple”, “living in a couple with a drug user”.
The prevalence of HCV risk practices was also docu-
mented using a set of questions extracted from the
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tionnaire (BBV-TRAQ) [17], which is a standardized
questionnaire specifically adapted for this purpose, and
also from the questionnaire used by Lucidarme et al. in
their longitudinal study [18]. HCV risk practices in the
previous month were assessed using a question about
the sharing of injecting paraphernalia (lending and bor-
rowing), needle sharing (lending and borrowing) and
straw sharing. We also evaluated HCV risk practices re-
lated to other skin penetration practices (sharing of toi-
letry items, tattoos/piercings in a non-professional
context and blood contact) in the previous month using
the BBV-TRAQ questionnaire. We built a variable called
“HCV risk practices”, which served as the study outcome
measure, and was defined as reporting at least one of
these HCV risk practices during the previous month.
Self-reported and medical questionnaires
Depressive symptoms and suicidal risk were assessed at
baseline and M12. For the former the Center for
Epidemiological Study Depression scale (CES-D) was used
during the phone interview. This enabled us to the com-
pute a global depression score ranging from 0 to 60, with
gender-specific cut-off values (23 for women and 17 for
men). For the latter, we used the Beck hopelessness scale
(BHS) which formed part of the patient self-administered
questionnaire. A cut-off score of nine on the BHS is pre-
dictive of possible suicide risk behavior [19].
HCV testing was performed under the principles of
routine clinical practice and was not something specific
to the trial. At each medical visit participants were asked
for the results of their most recent HCV test (positive,
negative or unknown if the patient could not remember
or if no test had ever been performed).
Statistical analysis
We used a chi-squared test and a Wilcoxon test for, re-
spectively, categorical and continuous variables, in order
to compare characteristics of patients at enrollment in
terms of HCV risk practices. The impact of time on
methadone treatment and potential risk factors on HCV
risk practices was assessed using a Logistic mixed model.
We tested whether the following factors were associated
with reporting at least one HCV risk practice: 1) socio-
demographic characteristics: sex, age, high school certifi-
cate, having children, employment, living in a couple,
unstable housing; 2) Alcohol consumption and drug
consumption other than opiates : alcohol dependence,
cocaine use, current injection; 3) Mental health prob-
lems: suicidal risk and depressive symptoms; 4) History
of drug use: history of drug overdose and of drug injec-
tion, age at first regular drug use and at first injection; 5)
Drug using network: drug using friends and living in a
couple (or not) with a drug user (or not).All variables associated with the outcome with a p-
value lower than 0.25 in univariate analysis were consid-
ered eligible for the multivariate model. A stepwise
procedure was used to identify the best model, and
variables were removed one at a time based on a P-value
of >0.05.
In addition, we performed a sensitivity analysis exclud-
ing the sharing of toiletry items from the outcome HCV
risk practices. To verify which correlates still remained




Table 1 describes the sample at baseline. Among the 176
individuals enrolled in the study and who had available
data about HCV risk practices, 15% were female and the
median (IQR) age was 32 (27-38) years. More than one
third (35%) had a high school certificate and 37% had
children. At baseline, half of the sample was employed
and almost two-thirds had unstable housing. Forty per-
cent were alcohol dependent, 28% reported using co-
caine during the previous month and 15% reported
current injecting drug use. The median (IQR) age at first
regular drug use was 20 (18-24) years. Almost one-third
of the sample was at risk of suicide and 39% had depres-
sive symptoms. With respect to living alone or not and
partner status, 55% reported living alone, 19% were liv-
ing in a couple but not with a drug user, 14% were living
with a drug user but not in a couple and 12% were living
in a couple with a drug user. At baseline, 3 (2%) individ-
uals reported being HIV positive, 26 (18.31%) HCV posi-
tive and 15% did not know their HCV status.
HCV risk practices during the 12-month follow-up
Table 2 presents all the HCV risk practices at M0 and
M12 using a univariate mixed model. At baseline, 11
(6%) individuals reported at least one HCV risk practice
related to drug use (sharing of needles, injecting para-
phernalia or straws) and 26 (16%) at least one HCV risk
practice related to non-drug use practices (sharing of
toiletry items, tattoos/piercings or blood contact). At
baseline, 34 (19%) individuals reported at least one HCV
risk practice (related or not to drug use).
Factors associated with at least one HCV risk practice
Table 3 shows the factors associated with at least one
HCV risk practice (related or not to drug use) in the
univariate analysis. The following socio-demographic
factors were associated with at least one HCV risk prac-
tice: female gender, being younger, having a high school
certificate. With respect to drug and alcohol use, alcohol
dependence, cocaine use and current drug injection were
associated with the outcome. In addition, a longer history
Table 1 Baseline characteristics (n (%) or median (IQR) of the sample used for the analyses (n = 176)): ANRS-Methaville
trial
At least one HCV risk practice
No Yes Total P†
n = 142 (80.7%) n = 34 (19.3%)
Gender
Male 128 (90.1) 21 (61.8) 149 (84.7) <10-3
Female 14 (9.9) 13 (38.2) 27 (15.3)
Age§ 34 (27-39) 29 (26-33) 32 (27-38) 0.02
French High School Certificate (Bac)
< Bac 95 (66.9) 20 (58.8) 115 (65.3) 0.37
≥ Bac 47 (33.1) 14 (41.2) 61 (34.7)
Having child(ren)
No 87 (61.3) 23( 67.7) 110 (62.5) 0.49
Yes 55 (38.7) 11 (32.3) 66 (37.5)
Employment
No 66 (46.5) 20 (58.8) 86 (48.9) 0.20
Yes 76 (53.5) 14 (41.2) 90 (51.1)
Unstable housing
No 54 (38.0) 12 (35.3) 66 (37.5) 0.77
Yes 88 (62.0) 22 (64.7) 110 (62.5)
Alcohol dependence‡
No 122 (88.4) 26 (76.5) 148 (86.1) 0.07
Yes 16 (11.6) 8 (23.5) 24 (14.0)
Cocaine consumption*
No 101 (74.8) 20 (58.8) 121 (71.6) 0.07
Yes 34 (25.2) 14 (41.2) 48 (28.4)
Current drug injection*
No 111 (86.72) 26 (76.5) 137 (84.6) 0.14
Yes 17 (13.28) 8 (23.5) 25 (15.4)
Suicidal risk**
No 90 (74.4) 14 (50.0) 104 (69.8) 0.01
Yes 31 (25.6) 14 (50.0) 45 (30.2)
Depressive symptoms***
No 87 (64.0) 17 (50.0) 104 (61.2) 0.14
Yes 49 (36.0) 17 (50.0) 66 (38.8)
Age at first regular drug use§ 21 (18-25) 20 (17-21) 20 (18-24) 0.02
Drug-using friends
No 42 (30.0) 7 (20.6) 49 (28.2) 0.27
Yes 98 (70.0) 27 (79.4) 125 (71.8)
Living
Alone 85 (61.2) 10 (29.4) 95 (54.9) 0.002
In a couple, not with a drug user 26 (18.7) 7 (20.6) 33 (19.1)
With a drug user, not in a couple 15 (10.8) 9 (26.5) 24 (13.9)
In a couple with a drug user 13 (9.4) 8 (23.5) 21 (12.1)
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Table 1 Baseline characteristics (n (%) or median (IQR) of the sample used for the analyses (n = 176)): ANRS-Methaville
trial (Continued)
VHC status
Negative 84 (68.9) 22 (73.3) 106 (69.7) 0.89
Positive 19 (15.6) 4 (13.3) 23 (15.1)
Unknown 19 (15.6) 4 (13.3) 23 (15.1)
†Chi-squared test or Wilcoxon test; §in years; ‡AUDIT score ≥13; *During the previous 4 weeks; **Beck ≥ 9; ***CES-D score >17 for males and >23 for females.
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practices. In terms of psychiatric comorbidities, individ-
uals presenting depressive symptoms or suicidal risk were
more likely to report HCV risk practices. Living in a
couple was associated with more HCV risk practices.
Compared with patients who were living alone, there was
an increasing risk of HCV risk practices for those living in
a couple with a non-drug user, for those not living in a
couple but with a drug user and for those living in a
couple and with a drug user. Furthermore, those who re-
ported having drug-using friends were more likely to re-
port HCV risk practices. HCV status was not associated
with the outcome.
The results of the multivariate analysis are presented
in Table 3. Five variables remained associated with
reporting at least one HCV risk practice: younger age,
suicidal risk, cocaine use, alcohol dependence and living
in a couple. Compared with patients who were living
alone, the increasing risk found in patients living in a
couple in the univariate analysis was confirmed after
multiple adjustment, i.e. an increased risk of HCV risk
practices was observed among individuals living in a
couple with a non-drug user and in those living in a
couple with a drug user. Individuals living with a drug
user but not in a couple exhibited similar risks to those
of participants who lived alone. HCV status was not
found to be associated with the outcome.
When performing the sensitivity analysis excluding the
sharing of toiletry items, two variables remained associ-
ated with reporting at least one HCV risk practice: suicidal
risk (IRR[CI95%] = 6.00 [1.80-20.02]) and living in a






At least 1 HCV risk practice associated with drug use
At least 1 HCV risk practice associated with other practices
At least 1 HCV risk practiceDiscussion
The findings of our study are important to better under-
stand factors associated with HCV risk practices in
methadone maintained opioid-dependent individuals.
Although the literature shows that methadone mainten-
ance treatment has a positive impact on HCV transmis-
sion risk reduction [20,21], it is also known that
methadone treatment is not enough to sufficiently reduce
the HCV transmission risk in opioid-dependent individ-
uals [22]. Indeed, in this study conducted on this popula-
tion, it appears that duration on MMT does not have a
significant impact on HCV risk practices. However, con-
sidering HCV prevalence in the whole population of drug
users, and also the high percentage of those unaware of
their HCV status (15% in our sample but much higher in
other studies (e.g. 65% in [23])), the impact of HCV risk
practices is a crucial point to address in this population.
These findings confirm the need for combined approaches
including access to needle and syringe programs and opi-
oid maintenance treatment [22,24].
When investigating correlates of HCV risk practices,
several factors remain associated in the final model.
First, people who were younger were more likely to re-
port such practices. A similar result was found elsewhere
[25]. In addition, Fuller et al. showed that among PWID,
HCV seroconverters tended to be younger [26], while
another study found that PWID with high-risk profiles
were younger [27,28]. This fact underlines the import-
ance of targeting younger drug users using specific inter-
ventions [29].
In our study, cocaine use was associated with HCV risk
practices. This finding reflects existing literature whichat M12 and impact of time on HCV risk practices:
seline (MO) M12 OR [95% CI] p
n (%) n (%) M12 vs. M0
1 (0.6%) 1 (0.7%) 1.22 [0.08-19.59] 0.89
3 (1.7%) 1 (0.7%) 0.40 [0.04-3.89] 0.43
9 (5.1%) 5 (3.5%) 0.64 [0.19-2.19] 0.48
11 (6.3%) 6 (4.1) 0.63 [0.21-1.90] 0.42
26 (16%) 18 (12%) 0.65 [0.30-1.45] 0.29
34 (19%) 22 (15%) 0.68 [0.33-1.41] 0.30
Table 3 Factors associated with at least one HCV risk practice: univariate and multivariate£ mixed models (n = 321
visits for 176 patients)
Number of visits (%)
or median (IQR)
Number of patients OR [95% CI] p aOR [95% CI] p
Gender
male 273 (85.1) 149 1
female 48 (14.9) 27 6.24 [1.88-20.79] 0.003
Age§ 32 (27-38) 0.89 [0.83-0.96] 0.004 0.91 [0.85-0.97] 0.01
High School Certificate
No 207 (64.5) 115 1
Yes 114 (35.5) 61 2.48 [0.94-6.54] 0.07
Having child(ren)
No 202 (62.9) 110 1
Yes 119 (37.1) 66 0.91 [0.35-2.41] 0.85
Employment
No 134 (41.7) 101 1
Yes 187 (58.3) 124 0.99 [0.43-2.31] 0.99
Unstable housing
No 109 (34.0) 77 1
Yes 212 (66.0) 129 0.71 [0.29-1.79] 0.47
Alcohol dependence ‡
No 279 (88.0) 158 1 1
Yes 38 (12.0) 28 4.20 [1.23-14.32] 0.02 4.19 [1.53-11.47] 0.01
Cocaine use*
No 245 (78.0) 149 1 1
Yes 69 (22.0) 56 3.81 [1.51-9.62] 0.01 2.52 [1.05-6.04] 0.04
Current drug injection*
No 274 (89.3) 156 1
Yes 33 (10.8) 27 3.64 [1.07-12.48] 0.04
Suicidal risk**
No 189 (74.4) 121 1 1
Yes 65 (25.6) 52 2.18 [0.92-5.17] 0.08 2.44 [0.99-6.02] 0.05
Depressive symptoms***
No 210 (66.9) 132 1
Yes 104 (33.1) 79 2.04 [0.84-4.96] 0.12
History of drug overdose
No 285 (88.8) 156 1
Yes 36 (11.2) 20 0.65 [0.13-3.10] 0.59
History of drug injection
No 165 (51.7) 89 1
Yes 154 (48.3) 86 1.64 [0.64-4.19] 0.31
Age at first regular drug use§ 20 (18-24) 0.84 [0.73-0.96] 0.01
Age at first injection§ 22 (19-26) 0.96 [0.84-1.10] 0.55
Drug using friends
No 114 (36.0) 81 1
yes 203 (64.0) 134 3.03 [1.23-7.43] 0.02
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Table 3 Factors associated with at least one HCV risk practice: univariate and multivariate£ mixed models (n = 321
visits for 176 patients) (Continued)
Living
Alone 171 (53.9) 110 1 1
In a couple, not with a drug user 78 (24.6) 56 2.65 [1.03-6.84] 0.04 4.16 [1.42-12.12] 0.02
With a drug user, not in a couple 36 (11.4) 32 4.78 [1.60-14.30] 0.01 2.46 [0.78-7.77] 0.13
In a couple with a drug user 32 (10.1) 27 7.95 [2.58-24.51] <10-3 9.85 [3.13-31.06] <10-3
VHC status
Negative 195 (69.4) 106 1
Positive 42 (15.0) 23 0.64 [0.17-2.40] 0.51
Unknown 44 (15.7) 23 0.74 [0.21-2.62] 0.64
£ n = 241 visits for 152 patients; 3 visits were removed after the residual analysis.
§ in years.
* During the previous 4 weeks.
** Beck ≥ 9.
*** CES-D score >17 for males and >23 for females.
‡ AUDIT score ≥13.
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of HCV seropositivity [30,31]. It is known that the more
frequent the drug intake in cocaine users the more they
engage in risk practices [32-34]. Alcohol use is also a well-
known factor of HCV and HIV risk practices in opioid-
dependent individuals on MMT [35]. In addition, alcohol
is also associated in PWID with unsafe sexual and inject-
ing practices [36]. Results from some studies have sug-
gested the effectiveness of implementing a “motivational-
based” intervention in order to reduce alcohol use among
HCV-infected individuals [37,38].
Our findings on HCV risk practices showed an associ-
ation with suicidal risk. Indeed, many studies investigat-
ing factors linked to attempted suicide, which is
intimately correlated with suicidal risk [39], have found
several associated risk practices, such as non-suicidal
self-harm incidents [40], risky health practices [41] and
overdoses [42]. Moreover, it has been shown that PWID
with suicidal ideation reported receiving and providing
used syringes more frequently [43].
Finally, methadone-maintained patients living in a
couple were more likely to report HCV risk practices.
This result is important as it provides the opportunity to
identify prevention strategies. More particularly, those
living in a couple with a non-drug using partner and a
drug-using partner, respectively, were four and ten times
more likely to report HCV risk practices than those who
were living alone. This at-risk group deserves special at-
tention. A common source of HCV infection in both
members of a couple has been already demonstrated,
supporting the hypothesis that HCV transmission is fre-
quent within couples [44] or at least in an intra-familial
context [10]. In some situations, “living in a couple” may
translate into a greater probability of knowing the seros-
tatus of one’s partner. In turn, this knowledge may have
an important impact on whether an individual engagesin either protective or indeed so-called “risk” practices.
However, in a study on a prevention intervention for
couples where one or both partners were PWID, El-
Bassel et al. [45] showed a high prevalence of HIV and
HCV, respectively 28% and 75%, and that a quarter of
those who tested positive in that study were unaware of
their status. Ignorance about one’s own status is a
phenomenon which deserves greater consideration and
investigation. It is not surprising that couples share toi-
letry items more than people living alone. However, be-
cause HCV infection is very prevalent in drug users, it
would seem important to pay attention to this risk prac-
tice in drug-using couples. A recent meta-analysis
showed that the risk of HCV infection through shared
drug preparation equipment was similar to that of
shared syringes and that the infection status of the shar-
ing partner was often unknown [46]. Moreover, it has
been shown that in regular heterosexual relationships,
injecting practices are not organized around HCV status
but are more influenced by the couple’s connection with
other drug users and more particularly whether they
share equipment with those outside the couple more fre-
quently [47]. In other words, the more HCV risk prac-
tices they are involved in outside the couple, the more
they share equipment with their partner. All these re-
sults should be taken into account to target methadone-
maintained patients, especially when their partner is a
drug user, and to individually adapt prevention counsel-
ling to reduce the risk of HCV transmission. One previ-
ous article has already pointed out that health education
materials for HCV prevention pay insufficient attention
to couples [48]. For example, transition to injection
within intimate partnerships is known to be common.
Couples-focused interventions should concentrate more
on this issue [49]. As has already been demonstrated for
HIV prevention regarding sexual risk practices in
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manage HCV risk transmission, without perpetuating
risk equivalence beliefs between HIV and HCV transmis-
sion [50]. More generally, as suggested in a recent study,
methadone maintenance treatment complemented with
psychosocial interventions can help to reduce HCV risk
practices [51].
The absence of any association between HCV sero-
positivity and HCV risk practices has to be discussed.
Indeed, it shows that those who are HCV positive are
not less likely to engage in HCV risk practices. This con-
firms the importance of setting up individually (or
couple-based) adapted prevention interventions to re-
duce the risk of HCV transmission. Moreover, 15% of in-
dividuals were not aware of their HCV status. This result
should encourage the promotion of HCV testing in the
drug using population and more particularly in
methadone-maintained patients.
Some limitations have to be acknowledged. First, as we
excluded triple co-dependent individuals from the trial,
it is possible that most-at-risk individuals were excluded.
Furthermore, evaluating changes in risk practices over
just one year in this small sample with a low prevalence
of risk practices at baseline is difficult. Data were for the
most part self-reported and accordingly social desirabil-
ity bias is possible. Nevertheless, the reliability of self-
reports in drug-using populations has already been dem-
onstrated [52]. Finally, one important limitation is that
we included non-drug related practices in the factors’
analysis yet it is well known that these practices are not
as important in HCV transmission as drug related risk
practices (including syringe- and paraphernalia-sharing).
Conclusions
Although the HCV epidemic is a growing health issue in
increasingly more countries, especially in drug-using
populations, current access to care and to prevention in-
terventions is not sufficient.
Identifying individuals at risk of HCV transmission
during methadone treatment, such as stimulant users,
alcohol dependent individuals, and those at suicidal risk,
is necessary to optimize response to treatment. Innova-
tive prevention approaches tailored to couples are ur-
gently needed and could decrease the risk of HCV in
this population.
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